Detection of Specific Antinuclear Reactivities in Patients with Negative Anti-nuclear Antibody Immunofluorescence Screening Tests

Clinical Chemistry - Tập 48 Số 12 - Trang 2171-2176 - 2002
Ilse Hoffman1, Isabelle Peene1, Eric Veys1, Filip De Keyser1
1Department of Rheumatology, Ghent University Hospital, De Pintelaan 185, Ghent 9000, Belgium

Tóm tắt

Abstract Background: For detection of anti-nuclear antibodies (ANAs) and antibodies to extractable nuclear antigens (ENAs), samples frequently are screened with indirect immunofluorescence (IIF); further determination of anti-ENA antibodies is performed only when the result is positive. However, because anti-ENA reactivities are found in samples with low fluorescence intensities, we determined anti-ENA antibodies in samples with negative IIF and thus calculated the sensitivity of IIF for specific ANAs. Methods: We collected 494 samples consecutively referred by rheumatologists for routine ANA testing. IIF on HEp-2 and HEp-2000 (HEp-2 cells transfected with Ro60 cDNA) and line immunoassay (LIA) for the detection of specific ANAs were performed on all samples. Results: Fluorescence intensities and patterns on HEp-2 were strongly correlated with those on HEp-2000 [Spearman ρ = 0.852 (P <0.001) and 0.838 (P <0.001), respectively]. Sixty-eight of 494 samples were positive on LIA, of which only 72% (confidence interval, 68–76%) were detected with HEp-2 and 75% (confidence interval, 70–78%) with HEp-2000. Of 291 samples negative on both substrates, 12 were positive on LIA. Connective tissue diseases were diagnosed in four of these patients and suspected in at least three others. Conclusion: The HEp-2 and HEp-2000 substrates perform comparably for fluorescence intensities and patterns and for detecting specific ANAs, but some patients with negative IIF show reactivity on LIA. We recommend testing for fine reactivities, regardless of the IIF result, when the clinical suspicion for rheumatic connective tissue disease is high.

Từ khóa


Tài liệu tham khảo

1995, Semin Arthritis Rheum, 24, 323, 10.1016/S0049-0172(95)80004-2

1995, Mayo Clin Proc, 70, 183, 10.4065/70.2.183

1988, Clin Rheumatol, 7, 465

1984, Arthritis Rheum, 27, 166, 10.1002/art.1780270207

1993, Manual of biological markers of disease, A2, 1

2000, Scand J Immunol, 52, 309, 10.1046/j.1365-3083.2000.00781.x

1996, Pathology, 28, 54, 10.1080/00313029600169533

1994, Clin Immunol Immunopathol, 73, 146, 10.1006/clin.1994.1181

1995, J Clin Lab Anal, 9, 218, 10.1002/jcla.1860090312

1993, Manual of biological markers of disease, A5, 1

1993, Manual of biological markers of disease, A3, 1

1999, Clin Exp Rheumatol, 17, 205

2001, Ann Rheum Dis, 60, 1131, 10.1136/ard.60.12.1131

1993, Br J Rheumatol, 32, 449, 10.1093/rheumatology/32.6.449

2002, Arthritis Res, 4, A30

2000, Scand J Rheumatol, 29, 116, 10.1080/030097400750001923

1999, BMJ, 318, 1322

2000, Clin Chem, 46, 893, 10.1093/clinchem/46.7.893

1999, J Clin Pathol, 52, 684, 10.1136/jcp.52.9.684

2000, Clin Rheumatol, 19, 291, 10.1007/s100670070048

1996, Arthritis Rheum, 39, 1055, 10.1002/art.1780390626

2002, Arthritis Res, 4, A31

2002, Ann Rheum Dis, 63, 929

Thông tin
Thông tin xuất bản

Clinical Chemistry

Tập 48 Số 12

2171-2176

Thông tin tác giả